After lectin affinity chromatography, the glycoproteins obtained from the samples were desalted using SepPak C18 cartridges, and then dried in a vacuum centrifuge. The glycoproteins were then mixed with immobilized trypsin (20% slurry v/w) for 20 min with gentle shaking, and then lyophilized. The lyophilized peptides were dissolved in 100 μL acetonitrile in 50 mM NH4HCO3 (pH 6.8) ( O-labeled peptides were mixed at a ratio of 1:1 for samples from recurrence and non-recurrence group and lyophilized.
Nano LC-electrospray ionization (ESI)-MS/MS
The lyophilized peptides were resuspended with 2% ACN in 0.1% formic acid, separated by nano LC, and then analyzed by online electrospray tandem mass spectrometry. The experiments were performed on a Nano Aquity UPLC system (Waters) connected to an LTQ Orbitrap XL mass spectrometer (Thermo Electron
Corp., Bremen, Germany) interfaced with an online nano electrospray ion source (Michrom Bioresources, Auburn, CA). The peptide separation was performed in a Michrom CAPTRAP (500 μm i.d. × 2 mm trap column) and a Michrom C18 (3.5 μm, glycoprotein digests (0.5 μg) were loaded onto the trap column and leached at a flow rate of 20 μL/min for 3 min. The mobile phases included 2% ACN in 0.1% formic acid (phase A and the loading phase) and 95% ACN in 0.1% formic acid (phase B). To achieve sufficient separation, a 60-min (for glycoprotein standards) or 90-min (for serum samples) linear gradient from 5% to 45% at phase B was employed. The flow rate of the mobile phase was set at 500 nL/min, and the electrospray voltage used was 1.6 kV. The linear gradient was adjusted to 90 min for serum samples analyses, while all other parameters remained unchanged. The LTQ Orbitrap XL mass spectrometer was operated in the data-dependent mode with an automatic switch between MS and MS/MS acquisition. The survey full-scan MS spectra with two microscans (m/z 350-1800) was acquired in Orbitrap at a resolution of 100,000 (at m/z 400) followed by eight MS/MS scans in LTQ trap. Dynamic exclusion was set to initiate a 60 s exclusion for ions analyzed twice within a 10 s interval.
Western blot
Western blot was conducted as described previously [2] . Briefly, the tested cells were subjected to lysis with RIPA buffer, and the cell lysates were separated by electrophoresis and transferred to PVDF membrane. After blocking, the membranes were incubated with primary antibodies, and subsequently incubated with horseradish peroxidase-conjugated secondary antibody. The signal was detected by exposure to X-ray film.
Plasmid construction, transfection, lentiviral production, infection, and establishment of stable cell lines
Human lentiviral shRNA against human QSOX1 was designed. pLKO.1-TRC cloning vector (Sigma-Aldrich, USA) was used. And pCDH-EF1-MCS-IRES-GFP vector (System Biosciences, USA) was used for QSOX1-S and mQSOX1-S overexpression.
Primers (Sangon Biotech, Shanghai, China) for constructing plasmids are shown in Supplementary Table S6 . The QSOX1-S, mQSOX1-S and QSOX1-shRNA oligos were purified, reannealed, and then cloned into lentiviral vectors. Lentiviruses were generated by transfecting lentiviral-expressing vectors pCDH-QSOX1-S, 
Cell Proliferation and Apoptosis Analyses
Cell proliferation was examined using Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). According to the manufacturer's instructions for Cell Counting Kit-8, harvested cells were seeded in 96-well plates at 1×103 per well in a final volume of added into each well, and the absorbance at 450 nm was measured after incubation for 2 hours at 37°C to calculate the number of viable cells. Apoptosis analyses were performed using propidium iodide (Keygen, Nanjing, China) and phycoerythrin (PE)-annexin apoptosis detection kit (BD Pharmingen, San Jose, CA, USA) on flow cytometry (Epics Altra, Beckman Coulter，USA).
Supplemental Figure S1 . The flowchart of this study. Glycoproteins from serum samples were digested into glycopeptides with trypsin.
Methods Purpose
Then, glycopeptides were enriched via lectin affinity chromatography from two different groups of sample, desalted, and then catalyzed by immobilized trypsin and Note: aa, amino acid residue. *N-linked glycosylation site. HBV, hepatitis B virus; AFP, alpha-fetoprotein; BCLC, the Barcelona Clinic Liver
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Cancer staging system.
